Datavant and UBC integrate capabilities to support evidence generation and patient access pathways 

Datavant and United BioSource Corporation (UBC) have announced a collaboration designed to support biopharmaceutical companies in generating real-world evidence (RWE) and improving patient access. The partnership combines Datavant’s data connectivity and privacy technologies with UBC’s capabilities in observational research, specialty therapies, and patient access programs. 

The collaboration establishes a coordinated framework that combines data-linkage infrastructure with observational research and access services. The aim is to help sponsors meet the operational and analytical requirements of late-phase studies while improving understanding of patient access patterns. Two initial joint offerings form the first phase of this work, focusing on real-world data (RWD) integration and enhanced visibility into access program performance. 

A key focus of the agreement is enabling secure, privacy-preserving linkage of structured and unstructured health data across a wide network of sources. Datavant supports connectivity across more than 350 organizations and provides access to patient-consented electronic health records (EHRs). UBC adds experience in RWE generation, epidemiology, registries, and patient access programs for specialty therapies. The combined capabilities are intended to support more consistent and scalable approaches to late-phase research and patient services without duplicating existing infrastructure. 

Arnaub Chatterjee, GM and President of Life Sciences at Datavant, stated that, 

“This collaboration is rebuilding the infrastructure of clinical research and patient support for the real-world era. Together with UBC, we’re connecting the evidence and operational layers of research, so studies can move faster and patients benefit from safer therapies.” 

The first offering, Modern Observational Research Study Designs, is intended to support longitudinal data collection and decision-grade insights on safety, value, and treatment pathways. The approach incorporates decentralized and direct-to-patient methods, which may broaden participation, reduce reliance on site-based data collection, and streamline operational processes. According to the companies, these designs can support more efficient enrollment and enable richer evidence development through linkage of multiple RWD sources, while maintaining established privacy and compliance standards. 

The second offering, Enhanced Patient Access Programs, focuses on linking information on access, adherence, and affordability with real-world patient behavior. Integrating patient access program data with secondary real-world datasets may provide additional insight into access barriers, prescriber patterns, patient outcomes, and overall program performance. These insights can assist sponsors in assessing and refining access strategies in a more structured and evidence-driven manner. 

Both organizations indicate that this initiative represents the beginning of a broader plan to integrate data and services to support biopharmaceutical research, safety monitoring, and patient access. Datavant enables the movement of more than 60 million healthcare records across thousands of organizations, while UBC provides evidence generation, patient safety, and access solutions across multiple therapeutic areas. Reflecting on the collaboration, Brett Huselton, SVP, Strategy, Partnership & Innovation at UBC, stated that: 

“Through the partnership with Datavant, we are not just enhancing offerings – we are creating new, connected solutions we believe will continue to deliver on the market’s demand for approaches that are sophisticated, efficient, and oriented around improving patient outcomes.”